PDF(Pubmed)
Abstract：
UNASSIGNED: The magnitude of potential benefits that hypothermic oxygenated perfusion (HOPE) may provide for liver transplantation (LT) patients compared to static cold storage (SCS) remains uncertain. In this systematic review and meta-analysis, we aimed to investigate the therapeutic effect that HOPE can offer LT recipients relative to SCS by synthesizing available evidence.
UNASSIGNED: A literature search was conducted in Embase, Medline, Web of Science, and the Cochrane database up to 1 June, 2023. The included studies were pooled for meta-analysis to synthesize their findings. Subgroup analysis was performed to investigate potential differences between HOPE and SCS for specific subgroups.
UNASSIGNED: A total of 11 studies comprising 1765 patients were included. Compared with SCS, HOPE was associated with a significant reduction in the incidence of early allograft dysfunction (EAD) (OR: 0.36, 95% CI: 0.26-0.50), as well as a noteworthy decrease in graft loss rate within one year (OR: 0.57, 95% CI: 0.33-0.97) and a lower occurrence of Clavien-Dindo grade IIIa or higher complications (OR: 0.62, 95% CI: 0.43-0.89). Subgroup analysis revealed that HOPE significantly reduced the one-year mortality rate, any biliary complications incidence, and acute rejection of transplanted liver rate in patients who received organs from donation after cardiac death (DCD).
UNASSIGNED: HOPE has demonstrated efficacy in reducing the incidence of EAD after LT and shows some potential in diminishing postoperative complications such as biliary complications and acute rejection. This ultimately leads to improved patient prognosis, particularly among those receiving DCD grafts.
UNASSIGNED: A literature search was conducted in Embase, Medline, Web of Science, and the Cochrane database up to 1 June, 2023. The included studies were pooled for meta-analysis to synthesize their findings. Subgroup analysis was performed to investigate potential differences between HOPE and SCS for specific subgroups.
UNASSIGNED: A total of 11 studies comprising 1765 patients were included. Compared with SCS, HOPE was associated with a significant reduction in the incidence of early allograft dysfunction (EAD) (OR: 0.36, 95% CI: 0.26-0.50), as well as a noteworthy decrease in graft loss rate within one year (OR: 0.57, 95% CI: 0.33-0.97) and a lower occurrence of Clavien-Dindo grade IIIa or higher complications (OR: 0.62, 95% CI: 0.43-0.89). Subgroup analysis revealed that HOPE significantly reduced the one-year mortality rate, any biliary complications incidence, and acute rejection of transplanted liver rate in patients who received organs from donation after cardiac death (DCD).
UNASSIGNED: HOPE has demonstrated efficacy in reducing the incidence of EAD after LT and shows some potential in diminishing postoperative complications such as biliary complications and acute rejection. This ultimately leads to improved patient prognosis, particularly among those receiving DCD grafts.
摘要：
■与静态冷藏（SCS）相比，低温氧合灌注（HOPE）可能为肝移植（LT）患者提供的潜在益处的大小仍不确定。在这篇系统综述和荟萃分析中，我们旨在通过综合现有证据,研究HOPE相对于SCS可以为LT患者提供的治疗效果.
■在Embase进行了文献检索，Medline,WebofScience,和Cochrane数据库直到6月1日，2023年。纳入的研究进行荟萃分析，以综合其发现。进行亚组分析以调查HOPE和SCS之间对于特定亚组的潜在差异。
■共纳入11项研究，包括1765名患者。与SCS相比，HOPE与早期同种异体移植功能障碍（EAD）的发生率显着降低相关（OR：0.36，95％CI：0.26-0.50），以及一年内移植物丢失率显著下降(OR:0.57,95%CI:0.33-0.97)和Clavien-DindoIIIa级或更高并发症发生率较低(OR:0.62,95%CI:0.43-0.89)。亚组分析显示，HOPE显着降低了一年的死亡率，任何胆道并发症的发生率，心脏死亡（DCD）后接受器官捐献的患者移植肝的急性排斥率。
■HOPE已证明可有效降低LT术后EAD的发生率，并有可能减少术后并发症，如胆道并发症和急性排斥反应。这最终导致改善患者预后，特别是那些接受DCD移植的人。
■在Embase进行了文献检索，Medline,WebofScience,和Cochrane数据库直到6月1日，2023年。纳入的研究进行荟萃分析，以综合其发现。进行亚组分析以调查HOPE和SCS之间对于特定亚组的潜在差异。
■共纳入11项研究，包括1765名患者。与SCS相比，HOPE与早期同种异体移植功能障碍（EAD）的发生率显着降低相关（OR：0.36，95％CI：0.26-0.50），以及一年内移植物丢失率显著下降(OR:0.57,95%CI:0.33-0.97)和Clavien-DindoIIIa级或更高并发症发生率较低(OR:0.62,95%CI:0.43-0.89)。亚组分析显示，HOPE显着降低了一年的死亡率，任何胆道并发症的发生率，心脏死亡（DCD）后接受器官捐献的患者移植肝的急性排斥率。
■HOPE已证明可有效降低LT术后EAD的发生率，并有可能减少术后并发症，如胆道并发症和急性排斥反应。这最终导致改善患者预后，特别是那些接受DCD移植的人。
